Alphyn Completes Enrollment in CLEAR-AD1 Global Phase 2b Clinical Trial of Novel Topical for Atopic Dermatitis

Multi-target therapeutic aims to treat all key and interconnected problems of atopic dermatitis ANNAPOLIS, Md., March 11, 2026 /PRNewswire/ -- Alphyn, a clinical-stage dermatology company developing the first Multi-Target Therapeutics® drug platform, announced today that it has completed...

Read More